· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Атмосфера. Новости кардиологии 2021 / N 1 Лечение пациентов со стабильной ишемической болезнью сердца: алгоритм антиангинальной терапии Ю.А. Карпов References 1. Rational pharmacotherapy of cardiovascular diseases. Chazov EI, Karpov YuA, editors. Moscow: Litterra; 2016. 784 p. (In Russian). 2. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal 2020 Jan;41(3):407-77. 3. Shalnova CA, Yarovaya EB, Makarova YuK, Kutsenko VA, Kapustina AV, Balanova YuA, Imayeva AE, Muromtseva GA. Are Russian men with intermittent claudication and/or angina pectoris have the same cardiovascular and all-cause mortality risks? The data of the prospective population-based study. Rational Pharmacotherapy in Cardiology 2020;16(5):787-97 (In Russian). 4. Stable angina pectoris. Recommendations of the Russian Cardiological Society 2020. Russian Journal of Cardiology 2020;25(11):201-50 (In Russian). 5. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDH, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder I, Wanner C, Williams B; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease. European Heart Journal 2021 Sep;42(34):3227-337. 6. Ferrari R, Camici PG, Crea F, Danchin N, Fox K, Maggioni AP, Manolis AJ, Marzilli M, Rosano GMC, Lopez-Sendon JL. Expert consensus document: a ‘diamond’ approach to personalized treatment of angina. Nature Reviews. Cardiology 2018 Feb;15(2):120-32. 7. Thadani U. Management of stable angina – current guidelines: a critical appraisal. Cardiovascular Drugs & Therapy 2016 Aug;30(4):419-26. 8. Husted SE, Ohman EM. Pharmacological and emerging therapies in the treatment of chronic angina. The Lancet 2015 Aug;386(9994):691-701. 9. National Institute for Health and Care Excellence (NICE). Stable angina: management. Clinical guideline [CG126]. Published: 2011 Jul 23. Last updated: 2016 Aug 25. Available from: https://www.nice.org.uk/guidance/cg126 Accessed 2021 Sep 24. 10. Klein WW, Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis. Coronary Artery Disease 2002 Dec;13(8):427-36. 11. Rousan TA, Mathew ST, Thadani U. Drug therapy for stable angina pectoris. Drugs 2017 Mar;77(3):265-84. 12. Pehrsson SK, Ringqvist I, Ekdahl S, Karlson BW, Ulvenstam G, Persson S. Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris. Clinical Cardiology 2000 Oct;23(10):763-70. 13. Emanuelsson H, Egstrup K, Nikus K, Ellstrom J, Glud T, Pater C, Scheibel M, Tisell A, Tötterman KJ, Forsby M. Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study. The TRAFFIC Study Group. American Heart Journal 1999 May;137(5):854-62. 14. Belsey J, Savelieva I, Mugelli A, Camm AJ. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis. European Journal of Preventive Cardiology 2015 Jul;22(7):837-48. 15. Wight LJ, VandenBurg MJ, Potter CE, Freeth CJ. A large scale comparative study in general practice with nitroglycerin spray and tablet formulations in elderly patients with angina pectoris. European Journal of Clinical Pharmacology 1992;42(3):341-2. 16. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, Hlatky MA. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999 May;281(20):1927-36. 17. Wei J, Wu T, Yang Q, Chen M, Ni J, Huang D. Nitrates for stable angina: a systematic review and meta-analysis of randomized clinical trials. International Journal of Cardiology 2011 Jan;146(1):4-12. 18. Ferratini M. Risk of rebound phenomenon during nitrate withdrawal. International Journal of Cardiology 1994 Jun;45(2):89-96. 19. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. European Heart Journal 2005 May;26(10):967-74. 20. Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, Montalescot G, Hsu A, Fox KA, Lincoff AM. Beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circulation: Cardiovascular Quality and Outcomes 2014 Nov;7(6):872-81. 21. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. The Lancet 2003 Jul;362(9377):7-13. 22. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999 Jun;318(7200):1730-7. 23. Hwang D, Lee JM, Kim HK, Choi KH, Rhee TM, Park J, Park TK, Yang JH, Song YB, Choi JH, Hahn JY, Choi SH, Koo BK, Kim YJ, Chae SC, Cho MC, Kim CJ, Gwon HC, Jeong MH, Kim HS; KAMIR Investigators. Prognostic impact of β-blocker dose after acute myocardial infarction. Circulation Journal 2019 Jan;83(2):410-7. 24. Dahl Aarvik M, Sandven I, Dondo TB, Gale CP, Ruddox V, Munkhaugen J, Atar D, Otterstad JE. Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. European Heart Journal. Cardiovascular Pharmacotherapy 2019 Jan;5(1):12-20. 25. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL; REACH Registry Investigators. Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012 Oct;308(13):1340-9. 26. Motivala AA, Parikh V, Roe M, Dai D, Abbott JD, Prasad A, Mukherjee D. Predictors, trends, and outcomes (among older patients ≥65 years of age) associated with beta-blocker use in patients with stable angina undergoing elective percutaneous coronary intervention: insights from the NCDR registry. JACC. Cardiovascular Interventions 2016 Aug;9(16):1639-48. 27. Zhang H, Yuan X, Zhang H, Chen S, Zhao Y, Hua K, Rao C, Wang W, Sun H, Hu S, Zheng Z. Efficacy of long-term β-blocker therapy for secondary prevention of long-term outcomes after coronary artery bypass grafting surgery. Circulation 2015 Jun;131(25):2194-201. 28. Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, Cottin Y, Aupetit JF, Bonnefoy E, Blanchard D, Cattan S, Steg G, Schiele F, Ferrières J, Juillière Y, Simon T, Danchin N. Beta-blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 2016 Sep;354:i4801. 29. Sorbets E, Steg PG, Young R, Danchin N, Greenlaw N, Ford I, Tendera M, Ferrari R, Merkely B, Parkhomenko A, Reid C, Tardif JC, Fox KM; CLARIFY investigators. Beta-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. European Heart Journal 2018 May;40(18):1399-407. 30. Neumann A, Maura G, Weill A, Alla F, Danchin N. Clinical events after discontinuation of β-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French healthcare databases. Circulation: Cardiovascular Quality and Outcomes 2018;11:e004356. 31. Rehnqvist N, Hjemdahl P, Billing E, Björkander I, Eriksson SV, Forslund L, Held C, Näsman P, Wallén NH. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). European Heart Journal 1996 Jan;17(1):76-81. 32. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003 Dec;290(21):2805-16. 33. Ried LD, Tueth MJ, Handberg E, Kupfer S, Pepine CJ; INVEST Study Group. A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension treatment strategy in the International Verapamil SR-Trandolapril Study (INVEST). Psychosomatic Medicine 2005 May-Jun;67(3):398-406. 34. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE, Seabra-Gomes R, Soler-Soler J, Weber S; Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. The Lancet 2004 Sep;364(9437):849-57. 35. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004 Nov;292(18):2217-25. 36. Frishman WH, Glasser S, Stone P, Deedwania PC, Johnson M, Fakouhi TD. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. The American Journal of Cardiology 1999 Feb;83(4):507-14. 37. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K; INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. European Heart Journal 2005 Dec;26(23):2529-36. 38. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007;67(3):393-405. 39. Tardif JC, Ponikowski P, Kahan T; ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. European Heart Journal 2009 Mar;30(5):540-8. 40. Döring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. Journal of Cardiovascular Pharmacology 1992;20(Suppl 3):S74-81. 41. Comparative analysis of efficacy and safety of nicorandil in treatment of patients with stable angina in comparison with therapy with beta-blockers, prolonged-acting nitrates and slow calcium channel blockers [abstract]. Russian Medical Journal. Medical Review 2019;6:24-30 (In Russian). 42. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. The Lancet 2002 Apr;359(9314):1269-75. 43. Martsevich SYu, Kutishenko NP, Deyev AD on behalf of the participants of the QUASAR study. Comparative assessment of antianginal efficacy and safety of nicorandil at the background of therapy with ß-adrenoblockers in ischemic heart disease patients with stable angina. Kardiologiia 2016;56(10):30-4 (In Russian). 44. Martsevich SYu, Lukina YuV, Kutishenko NP, Akimova AV, Voronina VP, Lerman OV, Gaysenok OV, Gomova TA, Yezhov AV, Kuimov AD, Libis RA, Matyushin GV, Mitroshina TN, Nechayeva GI, Reznik II, Skibitskiy VV, Sokolova LA, Chesnikova AI, Dobrynina NV, Yakushin SS. Assessment of adherence to treatment and factors affecting it in patients with stable ischemic heart disease during therapy with nicorandil. Rational Pharmacotherapy in Cardiology 2017;13(6):776-86 (In Russian). 45. Voronina VP, Martsevich SYu, Kutishenko NP, Deyev AD on behalf of the participants of KVAZAR study. Assessment of antiischemic and antianginal effects of nicorandil by treadmill test, under the framework of KVAZAR study. Russian Journal of Cardiology 2017;22(3):97-103 (In Russian). 46. Martsevich SYu, Kutishenko NP, Deyev AD on behalf of the participants of KVAZAR study. The assessment of nicorandil effect on the quality of life in patients with stable angina in KVAZAR study. Rational Pharmacotherapy in Cardiology 2016;12(6):654-60 (In Russian). 47. Martsevich SYu, Lukina YuV, Kutishenko NP, Semenova YuV. Comparison of the outcomes of the prolonged antianginal therapy use in stable coronary artery disease patients according to the data of randomized and observational studies. Contemporary Clinical Trials Communications 2021 Feb 17;21:100743. 48. Zhao XT, Zhang CF, Liu QJ. Meta-analysis of nicorandil effectiveness on myocardial protection after percutaneous coronary intervention. BMC Cardiovascular Disorders 2019 Jun;19(1):144. 49. Soboleva GN, Gostishchev RV, Rogoza AN, Kotkina TI, Samko AI, Karpov YuA. The effect of pharmacological preconditioning with nicorandil before elective coronary stenting on the long-term prognosis of patients with stable coronary artery disease. Rational Pharmacotherapy in Cardiology 2020;16(2):191-8 (In Russian). 50. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E; MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007 Apr;297(16):1775-83. 51. Wilson SR, Scirica BM, Braunwald E, Murphy SA, Karwatowska-Prokopczuk E, Buros JL, Chaitman BR, Morrow DA. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. Journal of the American College of Cardiology 2009 Apr;53(17):1510-6. 52. Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, Davidson-Ray L, Witkowski A, Mulkay AJ, Osmukhina A, Farzaneh-Far R, Ben-Yehuda O, Stone GW, Ohman EM. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. Circulation 2016 Jan;133(1):39-47. 53. McCarthy CP, Mullins KV, Kerins DM. The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent. European Heart Journal. Cardiovascular Pharmacotherapy 2016 Oct;2(4):266-72. 54. European Medicines Agency. Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution). Available from: https://www.ema.europa.eu/en/documents/referral/questions-answers-review-medicines-containing-trimetazidine-20-mg-tablets-35-mg-modified-release/ml-oral-solution_en.pdf Accessed 2021 Sep 24. 55. European Medicines Agency. Assessment report for trimetazidine containing medicinal products. Available from: https://www.ema.europa.eu/en/documents/referral/trimetazidine-article-31-referral-assessment-report_en.pdf Accessed 2021 Sep 24. 56. Peng S, Zhao M, Wan J, Fang Q, Fang D, Li K. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. International Journal of Cardiology 2014 Dec;177(3):780-5. 57. Ferrari R, Ford I, Fox K, Challeton JP, Correges A, Tendera M, Widimský P, Danchin N; ATPCI investigators. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. The Lancet 2020 Sep;396(10254):830-8. 58. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. The Lancet 2010 Jun;375(9732):2161-7. 59. Singh JA, Yu S. Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: a study of Medicare claims. Arthritis Research & Therapy 2016 Sep;18(1):209. 60. Okafor ON, Farrington K, Gorog DA. Allopurinol as a therapeutic option in cardiovascular disease. Pharmacology & Therapeutics 2017 Apr;172:139-50. 61. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, Pepine CJ. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). European Heart Journal 2008 May;29(10):1327-34. 62. Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B, Airaksinen KEJ, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008 Sep;118(12):1250-8. 63. Ho JE, Bittner V, Demicco DA, Breazna A, Deedwania PC, Waters DD. Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (Data from the Treating to New Targets [TNT] trial). The American Journal of Cardiology 2010 Apr;105(7):905-11. 64. Pauly DF, Johnson BD, Anderson RD, Handberg EM, Smith KM, Cooper-DeHoff RM, Sopko G, Sharaf BM, Kelsey SF, Merz CN, Pepine CJ. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: a double-blind randomized study from the National Heart, Lung and Blood Institute Women’s Ischemia Syndrome Evaluation (WISE). American Heart Journal 2011 Oct;162(4):678-84. 65. Ong P, Athanasiadis A, Sechtem U. Pharmacotherapy for coronary microvascular dysfunction. European Heart Journal. Cardiovascular Pharmacotherapy 2015 Jan;1(1):65-71. 66. Yamabe H, Namura H, Yano T, Fujita H, Kim S, Iwahashi M, Maeda K, Yokoyama M. Effect of nicorandil on abnormal coronary flow reserve assessed by exercise 201Tl scintigraphy in patients with angina pectoris and nearly normal coronary arteriograms. Cardiovascular Drugs and Therapy 1995;9:755-61. 67. Chen JW, Lee WL, Hsu NW, Lin SJ, Ting CT, Wang SP, Chang MS. Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina. The American Journal of Cardiology 1997;80:32-8. 68. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). Circulation Journal 2014;78(11):2779-801. 69. Tsuburaya R, Takahashi J, Nakamura A, Nozaki E, Sugi M, Yamamoto Y, Hiramoto T, Horiguchi S, Inoue K, Goto T, Kato A, Shinozaki T, Ishida E, Miyata S, Yasuda S, Shimokawa H; NOVEL Investigators. Beneficial effects of long acting nifedipine on coronary vasomotion abnormalities after drug-eluting stent implantation: the NOVEL study. European Heart Journal 2016 Sep;37(35):2713-21.    [ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]